30.20
—
Close of 4 Nov 2026, in ILA
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Allmed Solutions
Its shares trade on Tel Aviv under the ticker ALMD.TA. It has been listed since 1 February 2007. In the fiscal year to 31 December 2021, it reported revenue of ILS 5,545 and net income of ILS 2.8m. At that date it held total assets of ILS 54.8m and shareholders' equity of ILS 50.4m.
Allmed Solutions Ltd. engages in the development, manufacture, and marketing of minimally invasive products internationally in various medical disciplines. Its products are used by physicians to treat a number of diseases and patients worldwide. The firm's product lines include: Covered Stents, which offers Ureteral Stent (URS), Round Posterior Stent (RPS), Triangular Prostatic Stent (TPS), Bulbar Stent (BUS) and Biliary Stent (BIS); Uro-Gynecology, which offers EndoFast Reliant System, EndoFast Resorb, EndoFast Reliant MN and EndoFast Reliant SCP; Type II Diabetes, which offers the Gastro-duodenal sleeve (GDS), as well as Cardiovascular, which offers WIRION EPD System. The firm's products serve patients with the following medical conditions: Pelvic Organ Prolapse (POP), Sacrocolpopexy, Male Stress Urinary Incontinence (SUI), Urethral/Ureteral Stricture, Carotid Stenosis, Biliary Stricture and Type II Diabetes.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 1 Feb 2007
- Website
- allium-medical.com ↗
Leadership
Pay as last reported
- Mr. Abraham NahmiasChairman of the Board, since 2014
- Mr. Ariel RubashkinChief Executive OfficerILS 737,000
- Mr. Shai TagFinance Director
- Mr. Erez KeinanVice President - Finance
- Mr. Shay ArotchasVice President - OperationsILS 745,000
- Mr. Ziv KalfonVice President-Engineering & TechnologyILS 734,000
- Mr. Daniel SpiraInternal Auditor
- Mr. Assaf AlperovitzDirector, since 2012ILS 2.0m
- Dr. Ehud GellerDirector
- DR. David MilchDirector
- Ms. Rinat GazitExternal Director
- Mr. Etan HillmanExternal Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Covered Stents product line serves global medical conditions like Pelvic Organ Prolapse and Carotid Stenosis.
- Uro-Gynecology offers EndoFast Reliant System for Male Stress Urinary Incontinence treatment.
- Cardiovascular WIRION EPD System addresses complex vascular conditions internationally.
Weaknesses
- Type II Diabetes product Gastro-duodenal sleeve (GDS) lacks global market presence.
- Biliary Stent (BIS) faces limited adoption in emerging healthcare markets.
- Triangular Prostatic Stent (TPS) has minimal international distribution channels.
Opportunities
- Expanding Covered Stents into new markets like Carotid Stenosis treatment globally.
- Increasing Uro-Gynecology product sales in the U.S. healthcare sector.
- Growing demand for Cardiovascular WIRION EPD System in European markets.
Threats
- Biliary Stricture treatment faces competition from established medical devices.
- Urethral/Ureteral Stricture market has rising regulatory hurdles in Europe.
- Type II Diabetes segment experiences price pressure from generic alternatives.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.